share_log

和誉-B(02256.HK):匹米替尼治疗TGCT患者的MANEUVER关键3期研究取得积极顶线结果以及匹米替尼治疗TGCT患者的最新1期研究结果

Hutchmed-B (02256.HK): Positive top-line results from the pivotal Phase 3 MANEUVER study of pexidartinib in treating TGCT patients, as well as the latest Phase 1 study results of pexidartinib in treating TGCT patients.

Gelonghui Finance ·  Nov 12, 2024 07:03

Gelonghui November 12th ∣ Hoyou-B (02256.HK) announced that on November 12, 2024, its subsidiary shanghai Hoyou Biomedical Technology Co., Ltd. ("Hoyou Biomedical") announced that the CSF-1R small molecule inhibitor Pimetryn, independently developed by Hoyou Biomedical, has achieved positive top-line results in the pivotal phase 3 MANEUVER study for the treatment of tenosynovial giant cell tumor (TGCT) patients, as well as the latest phase 1 study results for Pimetryn in treating TGCT.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment